Councils & Committees

​Pharmacy and Therapeutics (P&T) Committee

P&T Committee Meeting Information

Upcoming Meetings

Dates

  • Tuesday, September 10, 2024; 12 p.m.-4 p.m.
  • Wednesday, September 11, 2024; 9 a.m.-4 p.m. 

Location

The September P&T Committee meetings will be held virtually

Register for the Webinars

Public Testimony

All members of the public may register to provide verbal or written testimony related to a drug or class of drugs included on the Statewide PDL at the P&T Committee meetings. Registration to present testimony during the meetings must be received by Tuesday, August 27, 2024. To register, please go to www.papdl.com and select "Public Testimony Registration." Written testimony will be accepted and must be submitted by Tuesday, August 27, 2024. Written testimony submissions will be distributed to all P&T Committee members prior to the meetings. All written testimony should be emailed to RA_PharmForms@pa.gov.

The list of drug classes for review will be posted prior to the meeting.

Related Links

The Department of Human Services (Department) appointed the P&T Committee to act in an advisory capacity to the Department and the Office of Medical Assistance Programs (OMAP) and provide an unbiased clinical perspective on the Department's Statewide Preferred Drug List (PDL). Recommendations from the committee must be reviewed and approved by the Secretary of the Department of Human Services.

Change Healthcare provides clinical and financial analysis support to the P&T Committee.

Committee Information

Composition and responsibilities of the committee:

  • Comprised of department medical directors, external physicians, pharmacists, consumer advocates, and specialists as needed for drug class reviews.
  • Recommend a clinically-based PDL with an emphasis on effectiveness, safety, and outcomes.
  • Recommend prior authorization guidelines for non-preferred drugs as well as certain preferred drugs using current community standards for prescribing.
  • Recommend Prospective and Retrospective Drug Utilization Review Program Review and Development.

 

Name

Specialty

Independent*

Department**

MCO

Ivonne Acrich, MD

Ad Hoc Child/Adolescent Psychiatrist

 

X

 

​Dale Adair, MD, FAPA

​Office of Mental Health & Substance Abuse Services Medical Director

​X

Christopher Antypas, PharmD

Community Pharmacist

X

 

 

Lawrence Appel, MD, SFHM

Medical Director, Office of Long Term Living

 

X

 

Meghan Brenkle, PharmD

PA Health & Wellness Pharmacist  X

Terri Cathers, PharmD,
Chair (tie-breaker vote only)

OMAP Pharmacy Director

 

X

 

​Michael Colvin, PharmD

​AmeriHealth Caritas & Keystone First HealthChoices & Community HealthChoices Pharmacist

​X

Sharon Connor, PharmD

Academic Pharmacist

X

 

 

​Molly DiMatteo, DO

​Family Practitioner

​X

​Oluwatoyin Fadeyibi, PharmD, MPH

​Community Behavioral Health Pharmacist

​X

Andrea Fox, MD

Internist

X

 

 

Mark Fuller, MD

Carelon Health of PA Medical Director      X

Donald Gerhart, RPh

Community Pharmacist

X

 

 

James Hancovsky, RPh, MBA

United Health Care Pharmacy Director

 

 

X

​David Kelley, MD

​OMAP Chief Medical Officer, Office of Medical Assistance Programs

​X

Peter Kreckel, RPh

Community Pharmacist

X

 

 

Renee Licwinko, RPh

Gateway Health Plan Pharmacist

 

 

X

Michele Musheno, RPh, MS

Academic/Hospital Pharmacist

X

 

 

​Geoffrey Neimark, MD

​Community Care Behavioral Health Psychiatrist

​X

Ian Paul, MD, Vice Chair

Pediatrician

X

 

 

Adam Raphael Rom, MD

Family Practitioner

X

 

 

Amy Saracino, DO

Ad Hoc Adult Psychiatrist

 

X

 

John Shand, MDPerformCare PA Medical Director  X

​Christopher Squillaro, DO

​Magellan Behavioral Health of PA Medical Director

​X

Kevin Szczecina, RPh

Geisinger Health Plan Pharmacist

 

 

X

​Fallan Vaisberg, PharmD, RPh

​Health Partners Plans Formulary Pharmacist

​X

Andreas Wali, MD

​Cardiologist

​X

Verlyn Warrington, MD

Bariatric Medicine Specialist/Family Medicine Doctor

X

 

 

Lloyd Wertz

Consumer/Family Advocate

X

 

 

​Lauren Zandier, PharmD

​UPMC For You Pharmacist

​X

Vacant

Consumer Representative

X

 

 

* - Independent Members are not employed by the Department
** - Department Members are employed by the Department on a full or part-time basis

Effective July 2, 2024 / Last modified July 5, 2024